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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease that is typically diagnosed late in its progression.
There is a need for biomarkers suitable for monitoring the disease progression at earlier stages to guide the develop-
ment of novel neuroprotective therapies. One potential biomarker, a-synuclein, has been found in both the familial
cases of PD, as well as the sporadic cases and is considered a key feature of PD. a-synuclein is naturally present in
the retina, and it has been suggested that early symptoms of the visual system may be used as a biomarker for PD.
Here, we use a viral vector to induce a unilateral expression of human wild-type a-synuclein in rats as a mechanistic
model of protein aggregation in PD. We employed functional magnetic resonance imaging (fMRI) to investigate whether
adeno-associated virus (AAV) mediated expression of human wild-type a-synuclein alter functional activity in the visual
system. A total of 16 rats were injected with either AAV-a-synuclein (n=7) or AAV-null (n=9) in the substantia nigra
pars compacta (SNc) of the left hemisphere. The expression of a-synuclein was validated by a motor assay and post-
mortem immunohistochemistry. Five months after the introduction of the AAV-vector, fMRI showed robust blood oxy-
gen level-dependent (BOLD) responses to light stimulation in the visual systems of both control and AAV-a-synuclein
animals. However, our results demonstrate that the expression of AAV-a-synuclein does not affect functional activation
of the visual system. This negative finding suggests that fMRI-based read-outs of visual responses may not be a sensi-
tive biomarker for PD.
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Significance Statement
We injected an adeno-associated virus (AAV) vector in rats to induce unilateral expression of human wild-type
a-synuclein in the substantia nigra, and in the ipsilateral striatum and superior colliculus (SC). This did not affect func-
tional activation of SC as probed with functional magnetic resonance imaging (fMRI). This negative finding discour-
ages the use of functional brain mapping of visually evoked activity as an indicator of regional expression of human
a-synuclein.
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Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder (Wirdefeldt et al., 2011) af-
fecting millions of people worldwide (Thomas and Beal,
2007). Although the disease is primarily considered to be
sporadic, there are familial versions caused by a mutation
in a single gene (Klein and Westenberger, 2012). These
hereditable forms of PD have led to the discovery of sev-
eral susceptibility genes, such as the SNCA gene (park1/
4) coding for a-synuclein. Aggregation of a-synuclein into
fibrils and Lewy bodies is hypothesized to develop long
before the diagnostic symptoms of tremor and postural
instability (Noyce et al., 2016). These aggregates have
been proposed to give rise to symptoms early in the
course of the disease, consequently, they may potentially
serve as biomarkers for the progression.
This study focuses on the visual system as several
studies have shown that the visual system is affected in
PD patients (Davidsdottir et al., 2005; Ekker et al., 2017;
Satue et al., 2017). Moreover, these changes have so far
failed to provide an unambiguous estimate of disease se-
verity (Ridder et al., 2017). This is likely because of PD
being diagnosed at a very late stage of disease progres-
sion, where patients are prone to suffer from a wide range
of visual changes related to normal aging (Ekker et al.,
2017). However, evidence of PD-related changes in vision
was provided by postmortem studies showing a-synu-
clein aggregation in the retinae of PD patients (Bodis-
Wollner et al., 2014). This finding lead to the hypothesis
that a-synuclein aggregation may cause changes in visual
responses measured in patients with PD.
A rodent model of a-synuclein expression in the sub-
stantia nigra pars compacta (SNc), mediated by the
adeno-associated virus (AAV) has shown to decrease the
number of spines of the dopaminergic cells, which in turn
have shown to influence the neuronal firing pattern in the
striatum (Andersen et al., 2018). In addition to the stria-
tum, the SNc also projects to the superior colliculus (SC)
which is the primary region for visual processing in rats
(Sefton et al., 2014). Further it was shown by Østergaard
and colleagues that this model also exhibits changes in
the latency of the visual evoked potential (VEP) measured
in the SC (Østergaard et al., 2020). The neuronal firing pat-
tern was measured invasively using electrophysiology
making it infeasible to apply in humans. Hence, a non-in-
vasive technique is desirable. MRI is a non-invasive bioi-
maging modality, which have been used to investigate
regional changes in brain structure of PD patients
(Lehéricy et al., 2014). Most MRI-based studies of PD pa-
tients have focused on changes in brain structure
(Niethammer et al., 2012; Weil et al., 2016). Functional
MRI (fMRI) measures the local changes in blood oxygen-
ation related to neuronal activity and has been applied in
PD patients to study changes in neuronal function. One of
these studies have shown changes in the iron load of cor-
tex and SNc in PD patients (Pyatigorskaya et al., 2014).
fMRI may also detect neuronal changes in the dopamine
release after a pharmacological challenge in the rodent
PD model (Kuebler et al., 2017) also used by Andersen
and colleagues (Andersen et al., 2018). This model mimics
the mechanistic changes of expressing human wild-type
a-synuclein in neurons of the substantia nigra (Decressac
et al., 2012).
The aim of this study was to use blood oxygen level-de-
pendent (BOLD) fMRI with a visual flickering full-field illu-
mination stimulation to examine potential functional
consequences of expressing human wild-type a-synu-
clein in the rodent. AAV carrying DNA encoding human
wild-type a-synuclein (hSNCA) was unilaterally injected in
SNc in rats with the aim of exogenously expressing the
human a-synuclein protein and was thereby expected to
cause an asymmetry of the BOLD response. In 2013,
Bailey et al. (2013) described how the cortex responds dif-
ferently to frequencies above and below a presentation
rate of 10Hz, therefore we have chosen to use presenta-
tion rates of 1 and 14Hz. The response to one frequency
could be more sensitive to changes introduced by ex-
pressing human a-synuclein compared with the response
to the other frequency, as responses to these two fre-
quencies may be governed by different mechanisms
(Bailey et al., 2013). We use the regions of interest (ROIs)
of the rodent visual system and then compared them to
the olfactory bulb (OB). The OB is used as a control re-
gion, as this region is easy to define and neutral with re-
gards to visual stimuli.
Materials and Methods
Subjects
All animal experiments were conducted in accordance
with the European Communities Council Directive (86/609/
EEC), and in accordance with Danish law on care of labora-
tory animals. The protocols were approved by the Danish
Animal Experiments Inspectorate (Forsøgsdyrstilsynet) before
the initiation of the study.
A total of 20 female Sprague Dawley (SD) rats (Taconic)
weighing ;225 g (corresponding to 10 weeks of age) on
arrival were included in the study. The rats underwent sur-
gery and cylinder test at one test site and were trans-
ported to another for MRI scanning. The animals
acclimatized to the new housing facility for at least two
weeks before imaging. The homecage environment in-
cluding light cycle, cages and enrichment was similar at
the two housing facilities. Both had a 12/12 h light/dark
cycle (lights on at 6 A.M.). The cages were enriched with
nesting material and a red plastic shelter. Access to food
(chow) and water was ad libitum.
Surgery
Before surgery, each rat was anesthetized using subcu-
taneous injections of Hypnorm (Lundbeck), midazolam
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5mg/ml (B. Braun), and saline in a 2:1:1 ratio yielding an
injection volume of 1.7 ml/kg. The rat was placed in a
stereotaxic frame and 0.1 ml Marcain (2.5mg/ml bupiva-
caine, AstraZeneca) was administered locally and sub-
cutaneously before incision. A small craniotomy (Ø= 1
mm) was made over the SNc of the left hemisphere (AP:
5.5 mm; ML: 12.0 mm; DV: 7.2 mm relative to breg-
ma; Paxinos and Watson, 1998) to allow for injection of
3 ml AAV 2/5 (3 1010 GC/ml; Vector biolabs), carrying
human wild-type a-synuclein (hSNCA) using methodol-
ogy as described previously (Andersen et al., 2018). Half
of the animals acted as controls by having the empty
viral vector injected. The animals were postoperatively
treated with buprenorphine 0.05mg/kg every eighth hour
for 4 d. The rats were single-housed after the surgery.
Cylinder test
To validate the expression of human wild-type a-synu-
clein in the basal ganglia, the rats were tested for motor
asymmetry 10 weeks after surgery. The animals were re-
corded with a video camera for 5 min, while they were
freely moving in a Plexiglas cylinder. Paw touches on the
side of the cylinder were counted offline and blinded to
the group. The ratio of touches of contralateral paw to
total touches was computed. Animals with an expression
of human a-synuclein were hypothesized to use the con-
tralateral paw less than the control animals.
MRI
Preparation for fMRI
Five months after the viral injection, the rats were anes-
thetized and scanned in a 7T Bruker Biospec (Bruker
BioSpec 70/20 USR) MRI scanner with an 80-mm radio
frequency (RF) transmit quadrature coil and a 20 mm sur-
face receive coil. The surface receive coil was fixed on top
of the head using masking tape. The position of the sur-
face ensured good signal coverage of the whole brain
having the largest signal sensitivity in the ROIs: the SC
and visual cortex. Sticky tack (Bantex) was placed in the
ears of the rats to reduce harmful effects of MR scanner
noise during scanning. The animals were scanned at the
same time of day, on separate days, to minimize variation
caused by the circadian rhythm.
Anesthesia during scan session. To reduce the un-
wanted effect of isoflurane on the BOLD signal, we used a
combination of low dose isoflurane and dexmedetomidine
(Dexdormitor, Orion Pharma). Anesthesia was induced
with isoflurane at 5% and adjusted to 2.5% while placing
a tail-vein catheter. Subsequently, dexmedetomidine was
infused at 0.05mg/kg/h (Pawela et al., 2009). When the
heart rate decreased to ;200 bpm, isoflurane was ad-
justed to 0.5% (in 1 l of oxygen:medical air, 8:2). The ani-
mals breathed spontaneously, and the respiration rate of
the animals was continuously monitored by a respiration
sensor pad (SA Instruments). Blood oxygen saturation
and heart rate was monitored transcutaneously using
pulse oximetry (Nonin). The core temperature of the ani-
mals was monitored with a rectal probe and used as feed-
back to maintain a constant temperature of 37°C using
heated air (SA Instruments). After 1 h of infusion, the infu-
sion rate of dexmedetomidine was increased to 0.1mg/
kg/h. This concentration is lower than what most literature
recommend (Pawela et al., 2009) because the vasocon-
strictive effects of dexmedetomidine made measuring
SpO2 challenging, and this lower concentration turned
out to be sufficient.
MRI protocols
Since the structural T1 weighted is not affected by an-
esthesia it was acquired before the fMRI. Before acquiring
the actual fMRI, online fMRI correlation analysis was ap-
plied at regular time intervals using a visual stimulus para-
digm. Online fMRI correlation analysis used the Analysis
of Functional NeuroImages (AFNI) software integrated
with the fMRI sequence (Cox, 1996). The online fMRI anal-
ysis was used to determine when the impact of isoflurane
on the neuronal response and BOLD signal was dimin-
ished, i.e., washed out. Typically, robust regional BOLD
responses were obtained after 180min.
Structural MRI to be aligned with fMRI included a whole
brain 3D T1-weighted fast low angle shot (FLASH) MRI [repe-
tition time (TR) = 1500ms, echo time (TE) = 8ms, inversion
time (IR) = 103,338.0ms, isotropic 0.2-mm3 voxels field of
view of 175 80 175mm3, matrix size=35 16 35).
The echoplanar image (EPI) MRI had an in-plane voxel
size of 0.313 0.313 mm with slice thickness of 0.500
mm, TR=1500ms, and TE=8.35ms, slice gap=0. The
Ernst flip angle was determined to 64°, based on T1 relax-
ation measurement of cortical gray matter obtained from
a separate session (data not shown). 42 coronal slices
covered the range from the caudal part of the OB to the
caudal part of the cerebellum.
Visual stimulation paradigm for fMRI
Visual stimulation was provided by five optical fibres (di-
ameter of 1.5 mm) of “warm white” light provided by a
light emitting diode (LED) source placed outside the scan-
ner. The optical fibres were placed in front of the animal
head as an array. The light intensity during the stimulation
was kept at 20 lx, measured at the level of the eyes using
a LED luxmeter (Extech).
The stimulation paradigm used a block design that was
generated by a micro1401 data acquisition unit (Cambridge
Electronic Design Ltd.) controlled from Spike2 version 7.20
synchronized to TTL triggers from the scanner. The block
design included six task blocks per trial repeated five times,
where each task block lasted for 21 s, equivalent to 14 TRs.
Each task block consisted of either 1- or 14-Hz light flicker.
These two frequencies were chosen as one should be just
above 10Hz, while the other should be well below, as 10Hz
is considered to be the threshold for saturation of the visual
cortex (Van Camp et al., 2006). Between task blocks there
were a pause of 14 TRs (21 s). The visual stimulation para-
digm was repeated five times at each stimulation frequency
yielding a total scan time of;4 h.
fMRI preprocessing
MRI data were analyzed using the FMRIB software li-
brary (FSL; Woolrich et al., 2009). To make a standard
brain template, the EPIs were aligned within subject using
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FMRIB’s linear image registration tool (FLIRT) and then
averaged across animals to construct a standard brain
template. This template was used for registration of the
data for later analysis.
Visual inspection caused exclusion of four rats, as
these could not be aligned to the standard template leav-
ing 16 to be analyzed; nine controls and seven AAV-
a-synuclein animals.
Statistical analysis
fMRI data were analyzed using a three-level statistical
analysis pipeline implemented in the FSL expert analysis
tool (FEAT). In the first level, the time course of each voxel
was fitted with a general linear model (GLM) to produce a
statistical map of the z scores of the correlation for each
voxel within each of the scans. Each voxel was corrected
for family-wise error with a p-threshold of p, 0.05.
Spatial smoothing was then applied using a Gaussian ker-
nel with full width half maximum of 0.5 mm. In the second
level, the z-statistical maps were averaged for each stimu-
lation frequency within each subject yielding two aver-
aged z-statistical maps per animal. Each voxel within the
averaged statistical map was corrected for family-wise
error with a p threshold of p=0.05. At the third and final
level, the averaged statistical maps were averaged within
the two groups for each of the two stimulation frequen-
cies. The group statistical maps were compared using an
unpaired comparison of the z-statistical maps between
the two groups within each frequency paradigm. For visu-
alization, the statistical maps were aligned to the standard
brain template (described above) and then superimposed
on the high-resolution structural MRI scan.
Structural ROIs of the SC and visual cortex were de-
fined manually based on rat brain atlases (Papp et al.,
2014; Kjonigsen et al., 2015; Sergejeva et al., 2015). The
OB was used as a control ROI. For each group there were
ROIs for OB, right SC, left SC, right VC and left VC. The
percent change of the BOLD within the ROIs were ex-
tracted from the z-statistical map of each rat using FEAT
query. Further, estimation statistics were conducted
using the website https://www.estimationstats.com/#/,
which is based on the methods described in (Ho et al.,
2019). Here, the data were compared with the common
control method within each stimulus paradigm, tested
using a two-sided permutation t test and corrected for
multiple comparisons. The resulting effect sizes and con-
fidence intervals (CIs) are listed in Table 1.
Immunohistochemistry
At the end of the scan session, the animal was given a
bolus 3 ml/kg of Hypnorm and midazolam was adminis-
tered SC. The animals were perfusion fixated with intra-
cardial potassium PBS (KPBS) for 3 min, followed by 4%
paraformaldehyde (PFA) premade with methanol. After
10–15min, the rat was decapitated, and the brain ex-
tracted. The brain was immersed in 4% PFA for 2 h, then
in phosphate buffer (PBS) with ,1% PFA for 24 h, and fi-
nally in KPBS.
Brains were fixed in 30% sucrose for 72 h before slic-
ing. Once fixed, they were dried and frozen with dry ice
and placed in a freezing microtome (Leica CM3050S) for
30min; 40-mm-thick coronal slices were cut and stored in
KPBS. All slices were stained within 5 d.
Brain sections were stained to validate the expression
pattern of the human wild-type SNCA protein. Before
staining, the tissue was quenched with hydrogen perox-
ide 3% to remove any traces of blood. The slices were
washed and incubated overnight with 4B12 (Thermo
Scientific) for human a-synuclein as the primary antibody
(concentration 1:1000). Subsequently, the slices were
washed and incubated with biotin conjugated anti-mouse
secondary antibody (Jackson ImmunoResearch) and
Table 1. Outcome of estimation statistics of the BOLD responses from each ROI
Figure Stimulus Control ROI ROI Effect size
CI (width 95.0%)
p valueLower bound Upper bound
3 1 Hz OB control OB a-synuclein 0.000905 0.00444 0.0502 0.981
VC control contra- 0.493 0.344 0.651 0.00022
VC control ipsi- 0.415 0.255 0.568 0.00099
VC a-synuclein contra- 0.336 0.0667 0.609 0.0452
VC a-synuclein ipsi- 0.429 0.127 0.68 0.0044
SC control contra- 1.2 0.885 1.52 0.000123
SC control ipsi- 1.15 0.816 1.57 0.000498
SC a-synuclein contra- 1.28 0.917 1.5 0.000133
SC a-synuclein ipsi- 1.22 0.958 1.4 0.000036
4 14 Hz OB control OB a-synuclein 0.038 0.243 0.14 0.722
VC control contra- 0.424 0.785 0.0208 0.0496
VC control ipsi- 0.257 0.528 0.0135 0.0926
VC a-synuclein contra- 0.258 0.638 0.0227 0.139
VC a-synuclein ipsi- 0.414 0.714 0.182 0.0012
SC control contra- 1.29 0.744 1.8 0.0006
SC control ipsi- 1.22 0.66 1.9 0.0006
SC a-synuclein contra- 1.38 0.585 2.01 0.001
SC a-synuclein ipsi- 1.21 0.273 1.72 0.0026
The 95 % CI are based on a two-sided permutation t-test with 5000 bootstraps. ROI; region of interest, Contra-; contralateral to the injection, Ipsi-; ipsilateral to
the injection, OB; olfactory bulb, VC; visual cortex, SC; superior colliculus.
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exposed using a 3,3¨-diaminobenzidine (DAB) reaction for
;20min. The stained slices were placed on gelatin cov-
ered glass slides, and visually examined using a light mi-
croscope (Axio scope.A1, Carl Zeiss Microimaging).
Results
Motor assessment of a-synuclein expression
To validate the expression and impact of human a-syn-
uclein in the rat basal ganglia, a-synuclein and control ani-
mals were tested for motor asymmetry in the cylinder test
(Andersen et al., 2018). Figure 1A shows the change in the
use of the forepaw contralateral to the injection site.
Control animals used both paws equally (ratio of 0.5),
while a-synuclein animals had a significantly different
mean ratio of affected/total touches ratio of 0.35 (t(14) =
2.8, p=0.01). The cylinder test confirmed that the function
of the striatum was unilaterally affected in the animals that
received the AAV-hSNCA injection, as expected with suc-
cessful injection of viral particles carrying the hSNCA-ex-
pressing vector.
Validation of expression of human a-synuclein
Immunohistochemical evaluation conducted after fMRI,
showed immunoreactivity toward human a-synuclein in
the SNc (Fig. 1E,F), in areas surrounding the SNc, and in
the striatum ipsilateral (Fig. 1B,C) to the injection site.
Interestingly, small inclusions of immunoreactivity were
observed in the optic layer of the ipsilateral SC (Fig. 1G).
Minor immunoreactivity was observed along the edges of
the tissue (Fig. 1C,D) which were not specific to the in-
jected hemisphere thus considered as unspecific immu-
noreactivity. Confirmation of a-synuclein in areas
ipsilateral to the injected hemisphere supports the obser-
vations from the cylinder test.
fMRI of the visual system
The z-statistical maps of the two groups are shown in
Figure 2 registered to a high-resolution anatomic scan.
Overall, there were detectable responses in both the SC
and the VC during light stimulation in both groups of rats.
A modest activation of cerebellar flocculus complex was
also observed. This is in line with previous studies where
visual stimulation has been applied (Van Camp et al.,
2006). Additionally, there was a response in the lateral ge-
niculate nucleus (LGN), as expected (Bailey et al., 2013).
Figure 1. Validation of the AAV-a-synuclein model. A) Cylinder test of the animals showing the ratio of touches by the contralateral
paw to the total number of touches. The control animals (in black) have a ratio of 0.51 indicating equal use of both paws. The a-syn-
uclein animals (in grey), have a ratio of 0.35 indicating that they use the paw contralateral of the injection less than the ipsilateral
paw. (B-G) Representative coronal sections stained for a-synuclein. B) 40x magnification of striatal neurons showing a-synuclein-
positive inclusions. C) 2,5x magnification of striatum showing a-synuclein immunoreactivity. D) 2,5x magnification of striatum con-
tralateral to the injection of AAV-a-synuclein. E) 40x magnification showing a-synuclein in cell somas in the substantia nigra. F) 2,5x
magnification of section showing the substantia nigra and the superior colliculus. G) 40x magnification showing a-synuclein immu-
noreactivity in the SC. The slices were stained with 4B12 (human WT alpha-synuclein).
Figure 2. Statistical group maps of BOLD fMRI responses to vis-
ual stimulation. The colour bar shows the thresholds for the z-
scores, as anything between -2 and 2 is considered insignificant.
The figure shows the group averages of activation as computed in
the level 3 FEAT analysis and registered to a high-resolution ana-
tomical scan. A) control group B) a-synuclein group. Visual stimu-
lation with flickering light robustly activated the superior colliculus
(SC) and in the visual cortex (VC). Additionally, the paraflocculus/
flocculus complex (Pfl/Fl) was activated.
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The BOLD changes from each of the ROIs are visualized
as points in the top panels of Figures 3, 4. Figure 3 shows
the responses to light flashing at 1Hz. Estimation statis-
tics comparing each ROI to the OB revealed a significant
response in both the VC and SC to the light flashing at
1Hz (Fig. 3). Table 1 lists the full results with effects sizes
and CIs. Figure 4 shows the responses to 14-Hz flashing
light. There was a statistically significant response to the
light stimulation in the SC. Furthermore, a significant dif-
ference was shown for VC ipsilateral to the injection of
Figure 3. Estimation statistics of percent change in BOLD during 1 Hz stimulation. The top panel shows the data points from each
ROI. OB of control group (blue), OB of a-synuclein group (yellow), VC of control group (green and red), VC of a-synuclein group
(purple and brown), SC of control group (pink and grey), SC of a-synuclein group (chartreuse and turquois). The ROI as designated
as contra- (contralateral) or ipsi- (ipsilateral) relative to the injection and expression of a-synuclein. The lower panel shows the differ-
ence of response when the response of the olfactory bulb in the control group is subtracted from each ROI. BOLD responses from
both the VC and SC differs significantly from the olfactory bulb. Asterisks refer to difference from control of p.0.05=not significant
(ns), *p,0.05, **p,0.01, and ***p,0.001.
Figure 4. Estimation statistics of percent change in BOLD during 14 Hz. The top panel shows the data points from each ROI. OB of con-
trol group (blue), OB of a-synuclein group (yellow), VC of control group (green and red), VC of a-synuclein group (purple and brown), SC
of control group (pink and grey), SC of a-synuclein group (chartreuse and turquois). The lower panel shows the difference of response
when the response of the olfactory bulb in the control group is subtracted from each ROI. Responses from the SC differ significantly
from OB. As does the contralateral VC from control group along with the response from the ipsilateral to the injection in the a-synuclein
group. Asterisks refer to difference from control of p.0.05=not significant (ns), *p,0.05, **p,0.01, and ***p,0.001.
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a-synuclein in the 14-Hz condition, with a magnitude of
0.414 (CI[0.714,0.182], p=0.0012). However, there
was also a difference in the control with an effect size of
0.424 (CI[0.785,0.0208], p=0.0496; Fig. 4). Taken
together, this suggests that the effect was not induced by
the expression of a-synuclein. Regardless, this potential
asymmetry was explored by comparing the VC within ani-
mals with a paired, permutation t test (Fig. 5). The control
group showed an insignificant difference between hemi-
spheres measured in the VC effect size of 0.167 (CI
[0.0163,0.324], p=0.0932). Similarly, there was no detect-
able difference between hemispheres in the a-synuclein
group effect size 0.156 (CI[0.268,0.0296], p=0.064).
In conclusion, the expression of the a-synuclein did not
induce detectable changes in the BOLD response within
animals.
Discussion
This study examined whether expression of a-synuclein
in the SNc is associated with abnormal visually evoked
brain activation. Using estimation statistics, we found ro-
bust BOLD-fMRI responses to the visual stimulus in the
SC in both control rats and a-synuclein rats. The BOLD
response in the VC turned out to be dependent on the
presentation rate of the stimulus. A fully developed ex-
pression of a-synuclein in the SNc, in the optic layer of
SC, and in the striatum did not induce any detectable
changes in BOLD-fMRI during visual stimulation. This in-
dicates that the level of neuronal activity measured dur-
ing visual stimulation was not altered by expression of
a-synuclein. Alternatively, the scan protocol used for
BOLD-fMRI at 7T was not sensitive enough to detect any
subtle differences between groups. However, the BOLD
responses in rat visual system reproduced the fre-
quency-dependence of the rodent visual cortex that was
previously reported (Van Camp et al., 2006). For VC, the
visually evoked BOLD responses tended to decrease at
stimulation frequencies above 10Hz, similar to the data
shown in another study (Bailey et al., 2013). The BOLD
signal in the SC did not show this frequency-response
behavior.
The AAV-model was validated both behaviorally and
with immunohistochemistry. Previously, asymmetry in the
cylinder test have been shown to be specific to a-synu-
clein expression and is not an effect of induced protein
expression with, e.g., green fluorescent protein (Andersen
et al., 2018). In the present study, it is shown that there is
indeed asymmetry in the use of forepaws as measured in
the cylinder test.
After the scan sessions the brains of each of the ani-
mals were stained for human wild-type a-synuclein to val-
idate that the model was developed. Both the cylinder
test and the immunohistochemistry confirmed a success-
ful development of human a-synuclein expression in the
SNc and connected areas such as the striatum and the
SC of the a-synuclein animals. Furthermore, it showed
that human a-synuclein was present in the SC ipsilateral
to the injection, however, this did not cause a detectable
asymmetry in the BOLD-response of the SC on visual
stimulation. Previously, the effect of human a-synuclein
expression in rats was measured using in vivo electro-
physiology. Here, subtle changes in the latency of VEPs in
the SC were shown (Østergaard et al., 2020). The tempo-
ral resolution of fMRI might not be suitable to detect
subtle increases in latency. This may explain the lack of
difference between the responses in the two hemispheres
in the a-synuclein animals. There is no direct correlation
between event-related potentials and BOLD-fMRI but the
g-band power (Huettel et al., 2004) and event-related
spectral perturbations (Engell et al., 2012) have been
shown to correlate with the BOLD response. The results
in this study support this discrepancy between the
techniques.
Interestingly, there was a significant difference in the
VC compared with the OB in the 14-Hz stimulation. A de-
creased BOLD response was observed in the VC ipsilat-
eral to the injection in the a-synuclein group and in the VC
contralateral to the injection in the control group com-
pared with the OB. However, this was not because of
asymmetry between the hemispheres in any of the
groups, suggesting that the observed effect was not
caused by the expression of a-synuclein.
In this study, the rodent eye is not considered to be im-
plicated. Also, the study by Østergaard et al. (2020) did
not show any statistically significant changes in the vis-
ual cortex after injection of AAV carrying human a-synu-
clein. If the rodent eye was functionally impacted, then
Figure 5. Comparison of differences within animals as paired.
Right and left hemisphere from the control group, are shown on
the left, and for the a-synuclein group on the right. The lower
panel shows the estimated mean difference between hemi-
spheres within the groups. The statistics does not reveal any
asymmetry induced by expression of human a-synuclein.
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both the SC and the VC would also have been affected.
The AAV virus was injected in the SNc and the virus par-
ticles tend to spread in the area proximal to the injection
site and via direct neuronal projections (Albert et al.,
2019). Furthermore, the SNc is not a retinorecipient re-
gion of the rat visual system (Sefton et al., 2014).
The AAV a-synuclein rat model of PD is not known to
cause large anatomic changes in the brain, however, it
does show a loss of dopaminergic cells (Decressac et al.,
2012). A study by Kuebler and colleagues suggests that
the change in dopamine can be measured by fMRI/PET
using an amphetamine challenge (Kuebler et al., 2017).
Generally, the functional consequences of expressing
human a-synuclein in vivo have been shown with other
MR-based methods than BOLD-fMRI. A study using diffu-
sion kurtosis imaging imaged a-synuclein in transgenic
mice (Khairnar et al., 2017). This technique evaluates
structural changes instead of the changes in oxygen me-
tabolism. Another study used MR spectroscopy to show
that bilaterally overexpressing a-synuclein in the striatum
caused changes in energy metabolism in rats (Cuellar-
Baena et al., 2016). This technique is sensitive to changes
in amounts of metabolites where BOLD detects changes
in the oxygen metabolism of larger populations of
neurons.
In rodent models of Alzheimer’s disease, changes have
been reported in functional connectivity patterns at early
stages of protein aggregation. This has been observed
using resting state fMRI (Grandjean et al., 2014). It can be
speculated that this could be caused by protein aggrega-
tion and that the specific composition of proteins may be
less important. Thus, evaluation of the AAV-model using
functional connectivity should be investigated further.
In human patients, Zhao and colleagues have described
changes in the BOLD signal of visual areas concerned
with the perception of movement (Zhao et al., 2014).
Further studies would be needed to study whether motion
perception is also affected in the AAV-model. Here, we
studied low-level visual processing but higher order
functions such as motion perception may be more sen-
sitive to the presence of a-synuclein. Generally, task-
related BOLD-fMRI is rarely used to study PD in animals
and humans. Often resting state fMRI and diffusion MRI
are applied (Lehericy et al., 2017; Tessitore et al., 2019).
The necessity of anesthesia is a major challenge for
fMRI studies in rodents. Anesthesia generally works by al-
tering the neuronal activity (Masamoto and Kanno, 2012).
Consequently, it will also affect the BOLD response.
Unlike urethane and a-chloralose, a mix of isoflurane and
dexmedetomidine may be used in longitudinal studies.
The anesthesia paradigm used in the present study
showed detectable and robust activation of the SC 3 h
after the induction of anesthesia. As the functional
changes in the SC are believed to be subtle, it cannot be
ruled out that the effect of the anesthesia may mask po-
tential functional differences.
In summary, this study shows that the fully developed
expression of a-synuclein in the SNc along with the optic
layer of SC and the striatum, did not induce any asymme-
try detectable using BOLD-fMRI during visual stimulation.
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